MCID: CND002
MIFTS: 52

Conduct Disorder

Categories: Mental diseases

Aliases & Classifications for Conduct Disorder

MalaCards integrated aliases for Conduct Disorder:

Name: Conduct Disorder 12 76 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:12995
ICD10 33 F91 F91.9
ICD9CM 35 312.9
MeSH 44 D019955
NCIt 50 C89329
UMLS 73 C0149654

Summaries for Conduct Disorder

Disease Ontology : 12 A specific developmental disorder marked by a pattern of repetitive behavior wherein the rights of others or social norms are violated.

MalaCards based summary : Conduct Disorder is related to impulse control disorder and oppositional defiant disorder. An important gene associated with Conduct Disorder is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Transmission across Chemical Synapses and Circadian entrainment. The drugs Methylphenidate and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and amygdala, and related phenotypes are Decreased viability in esophageal squamous lineage and behavior/neurological

Wikipedia : 76 Conduct disorder (CD) is a mental disorder diagnosed in childhood or adolescence that presents itself... more...

Related Diseases for Conduct Disorder

Diseases related to Conduct Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
# Related Disease Score Top Affiliating Genes
1 impulse control disorder 32.7 DRD2 DRD4
2 oppositional defiant disorder 31.9 COMT DBH DRD2 DRD4 MAOA SLC6A3
3 depression 30.8 MAOA SLC6A4 TPH1
4 anxiety 30.4 COMT MAOA SLC6A4 TPH1
5 antisocial personality disorder 30.0 ALDH2 COMT DRD2 MAOA SLC6A3 SLC6A4
6 opiate dependence 29.9 DRD2 SLC6A4 TPH1
7 borderline personality disorder 29.9 COMT MAOA SLC6A4 TPH1
8 alcohol abuse 29.8 ALDH2 DRD2 DRD4 SLC6A4
9 personality disorder 29.8 ALDH2 COMT DRD2 DRD4 MAOA SLC6A3
10 attention deficit-hyperactivity disorder 29.7 COMT DBH DRD2 DRD4 DRD5 MAOA
11 substance dependence 29.7 DRD2 DRD4 DRD5 MAOA SLC6A3 SLC6A4
12 autism spectrum disorder 29.6 OXTR RBFOX1 SLC6A4
13 substance abuse 29.6 COMT DBH DRD2 DRD4 DRD5 MAOA
14 tic disorder 29.4 DRD2 DRD4 DRD5 SLC6A3
15 autism 29.3 COMT DBH DRD2 DRD4 MAOA OXTR
16 disease of mental health 29.3 COMT DRD2 DRD4 MAOA OXTR SLC6A3
17 alcohol dependence 29.3 ALDH2 COMT DBH DRD2 DRD4 MAOA
18 gilles de la tourette syndrome 29.1 COMT DBH DRD2 DRD4 DRD5 SLC6A3
19 major depressive disorder 29.0 COMT DRD2 DRD4 MAOA OXTR SLC6A3
20 bipolar disorder 29.0 COMT DBH DRD2 DRD4 DRD5 GRIN1
21 panic disorder 29.0 ADORA2A COMT MAOA SLC6A4 TPH1
22 tobacco addiction 28.8 ALDH2 COMT DRD2 MAOA SLC6A3 SLC6A4
23 schizophrenia 28.4 ADORA2A COMT DBH DRD2 DRD4 DRD5
24 heart conduction disease 11.3
25 cardiomyopathy, dilated, 1e 11.3
26 familial progressive cardiac conduction defect 11.1
27 wolff-parkinson-white syndrome 11.1
28 progressive familial heart block, type ia 11.0
29 cardiac conduction defect 11.0
30 atypical depressive disorder 10.2 MAOA SLC6A4
31 delusional disorder 10.2 DRD2 DRD4
32 phobia, specific 10.2 COMT MAOA
33 schizophreniform disorder 10.2 COMT DRD2
34 polysubstance abuse 10.2 COMT DRD2
35 tardive dyskinesia 10.2 COMT DRD2
36 dependent personality disorder 10.2 DRD4 MAOA
37 alcohol-induced mental disorder 10.2 DRD2 SLC6A3 SLC6A4
38 premature ejaculation 10.2 COMT SLC6A3 SLC6A4
39 alcoholic psychosis 10.2 DRD2 SLC6A3 SLC6A4
40 migraine without aura 10.1 DRD2 DRD4 SLC6A4
41 dysthymic disorder 10.1 MAOA SLC6A4
42 phobic disorder 10.1 COMT MAOA SLC6A4
43 kleptomania 10.1 MAOA SLC6A4
44 social phobia 10.1 DRD2 MAOA SLC6A4
45 paranoid schizophrenia 10.1 COMT MAOA SLC6A4
46 separation anxiety disorder 10.1 DRD4 OXTR SLC6A3
47 schizoaffective disorder 10.1 COMT DRD2 SLC6A4
48 periodic limb movement disorder 10.1 DRD2 SLC6A4
49 long qt syndrome 1 10.1
50 chronic fatigue syndrome 10.1 COMT MAOA SLC6A4

Comorbidity relations with Conduct Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Alzheimer Disease
Deficiency Anemia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Conduct Disorder:



Diseases related to Conduct Disorder

Symptoms & Phenotypes for Conduct Disorder

GenomeRNAi Phenotypes related to Conduct Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.23 ALDH2 COMT DBH DRD4 DRD5 GRIN1

MGI Mouse Phenotypes related to Conduct Disorder:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.37 ADORA2A ALDH2 CAMK2A COMT DBH DRD2
2 homeostasis/metabolism MP:0005376 10.22 ADORA2A ALDH2 CAMK2A COMT DBH DRD2
3 cardiovascular system MP:0005385 10.18 ADORA2A ALDH2 COMT DBH DRD2 DRD5
4 growth/size/body region MP:0005378 10.17 ADORA2A ALDH2 CAMK2A DBH DRD2 GRIN1
5 nervous system MP:0003631 10.1 ADORA2A ALDH2 CAMK2A COMT DBH DRD2
6 endocrine/exocrine gland MP:0005379 10.06 ALDH2 COMT DBH DRD2 DRD5 OXTR
7 integument MP:0010771 10.02 ADORA2A ALDH2 CAMK2A DBH DRD2 OXTR
8 muscle MP:0005369 9.87 ADORA2A ALDH2 DRD2 OXTR SLC6A3 SLC6A4
9 normal MP:0002873 9.7 DBH DRD2 DRD5 GRIN1 OXTR SLC6A3
10 reproductive system MP:0005389 9.5 ALDH2 COMT DRD2 GRIN1 OXTR RBFOX1
11 taste/olfaction MP:0005394 8.8 DRD2 GRIN1 SLC6A3

Drugs & Therapeutics for Conduct Disorder

Drugs for Conduct Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 113-45-1 4158
2
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
4
Dextroamphetamine Approved, Illicit Phase 4,Phase 2 51-64-9 5826
5
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
6
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
7
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 16590-41-3 5360515
8
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
9
Oxcarbazepine Approved Phase 4 28721-07-5 34312
10
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
11
Aripiprazole Approved, Investigational Phase 4,Not Applicable 129722-12-9 60795
12
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2 300-62-9 5826 3007
13
Levodopa Approved Phase 4 59-92-7 6047
14
Carbidopa Approved Phase 4 28860-95-9 34359 38101
15
Citalopram Approved Phase 4 59729-33-8 2771
16
Sertraline Approved Phase 4,Phase 2 79617-96-2 68617
17
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
18
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
19
Ropinirole Approved, Investigational Phase 4 91374-21-9, 91374-20-8 497540 5095
20
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
21
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
22
Naratriptan Approved, Investigational Phase 4 121679-13-8, 143388-64-1 4440
23
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
24 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
25 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Serotonin Antagonists Phase 4,Phase 3,Phase 2
29 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Dopamine Antagonists Phase 4,Phase 3,Phase 2
32 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
35 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
36 Anticonvulsants Phase 4,Phase 2
37 GABA Agents Phase 4
38 Antimanic Agents Phase 4,Phase 3
39 Anti-Obesity Agents Phase 4,Phase 2
40 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Neuroprotective Agents Phase 4,Phase 2
42 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Narcotic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Narcotics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
45 Sodium Channel Blockers Phase 4
46 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
47 Cytochrome P-450 CYP3A Inducers Phase 4
48 Diuretics, Potassium Sparing Phase 4
49 Analgesics Phase 4,Phase 2,Phase 3
50 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 253)
# Name Status NCT ID Phase Drugs
1 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
2 Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study) Unknown status NCT00794625 Phase 4 Valproate;Risperidone;Placebo;Stimulant medication
3 Methylphenidate in ADHD With Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
4 Topiramate in the Treatment of Pathological Gambling Unknown status NCT00245583 Phase 4 topiramate (Topomax)
5 The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States. Completed NCT00154362 Phase 4 Oxcarbazepine
6 Trial of Aripiprazole in the Treatment of CD in Adolescents Completed NCT00250705 Phase 4 Aripiprazole
7 Early Prevention of Conduct Problems Completed NCT00051714 Phase 4
8 Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder Completed NCT00228046 Phase 4 Divalproex Sodium;Methylphenidate;Dextroamphetamine;Mixed Amphetamine Salts
9 Treatment of Severe Childhood Aggression (The TOSCA Study) Completed NCT00796302 Phase 4 Methylphenidate HCl;Risperidone;Placebo
10 Depakote (Divalproex Sodium) for Children With Temper Dysregulation and Severe Mood Swings Completed NCT02078596 Phase 4 Divalproex
11 Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa Completed NCT01683253 Phase 4 Levodopa/Carbidopa(200mg/50mg);Dopaminergic Agonists
12 Escitalopram for the Treatment of Self-Injurious Skin Picking Completed NCT00115011 Phase 4 Escitalopram
13 Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania Completed NCT00118014 Phase 4 Sertraline
14 Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention Completed NCT01528007 Phase 4 Naltrexone pharmacotherapy;Placebo
15 Acamprosate in the Treatment of Pathological Gambling Completed NCT00571103 Phase 4 acamprosate
16 Olanzapine in the Treatment of Hair Pulling (Trichotillomania) Completed NCT00182507 Phase 4 Olanzapine
17 Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany Completed NCT00406354 Phase 4 Atomoxetine;Placebo
18 A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00190775 Phase 4 Atomoxetine Hydrochloride;Placebo
19 Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
20 Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance? Completed NCT01127607 Phase 4 lisdexamfetamine
21 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Completed NCT02048241 Phase 4 Intuniv
22 Cognitive Behavioral Therapy for Adolescents With Attention-Deficit / Hyperactivity Disorder Recruiting NCT02566824 Phase 4 Methylphenidate or amphetamine product
23 Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk Not yet recruiting NCT03781765 Phase 4 Methylphenidate;Atomoxetine
24 Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated NCT00282165 Phase 4 naratriptan;placebo
25 Multidimensional Treatment Foster Care for Adolescents Withdrawn NCT01726361 Phase 4
26 Long-Term Lithium Treatment for Aggressive Conduct Disorder Completed NCT00000385 Phase 3 Lithium;Placebo
27 A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation Completed NCT00266552 Phase 3 risperidone
28 A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation Completed NCT00250354 Phase 3 Risperidone oral solution
29 Randomized Control Trial of an Animal-Assisted Intervention With Adjudicated Youth Completed NCT01594606 Phase 3
30 Treating Tobacco Dependence in Adolescents With Co-occurring Psychiatric Disorders Completed NCT00618943 Phase 3
31 Adventure: Teacher Delivered Personality-targeted Interventions for Substance Misuse Completed NCT00776685 Phase 2, Phase 3
32 Personality-targeted Interventions for Adolescent Alcohol Misuse Completed NCT00344474 Phase 2, Phase 3
33 Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers Completed NCT01416805 Phase 3
34 Omega-3 Supplements to Reduce Antisocial Behaviour in Young Offenders Completed NCT03627312 Phase 2, Phase 3
35 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3 Risperdal
36 A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder Completed NCT00922636 Phase 2, Phase 3 LY2216684;Methylphenidate;Placebo (tablet);Placebo (capsule)
37 Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling Completed NCT00438776 Phase 3 olanzapine;sugar pill
38 Minimal and Brief Treatments for Pathological Gamblers Completed NCT00203645 Phase 3
39 Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling Completed NCT00132119 Phase 2, Phase 3 nalmefene HCl
40 Drug Treatment for Pathologic Gambling Disorder Completed NCT00053677 Phase 3 Naltrexone;Placebo
41 Treatment of Children With Peer Related Aggressive Behavior Completed NCT01406067 Phase 3
42 The Effect of Transcranial Direct Current Stimulation on Decision Making and Cognitive Flexibility in Gambling Disorder Completed NCT03477799 Phase 3
43 Dronabinol in Trichotillomania Recruiting NCT03530800 Phase 2, Phase 3 Dronabinol;Placebo
44 Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders Recruiting NCT03146130 Phase 3
45 Modulating Inhibitory Control Networks in Gambling Disorder With Theta Burst Stimulation Recruiting NCT03669315 Phase 3
46 How the Adolescent Inpatients Are Rehabilitated After Discharge Terminated NCT01709526 Phase 2, Phase 3
47 A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder Terminated NCT00965419 Phase 2, Phase 3 Edivoxetine
48 Community Reinforcement Approach and Family Training (CRAFT) for Problem Gambling Unknown status NCT01340274 Phase 2
49 Testing a New Therapy for Trichotillomania Unknown status NCT00872742 Phase 2
50 Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study Unknown status NCT02934919 Phase 2 Nalmefene

Search NIH Clinical Center for Conduct Disorder

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: conduct disorder

Genetic Tests for Conduct Disorder

Anatomical Context for Conduct Disorder

MalaCards organs/tissues related to Conduct Disorder:

41
Brain, Testes, Amygdala, Cortex, Eye, Heart, Thyroid

Publications for Conduct Disorder

Articles related to Conduct Disorder:

(show top 50) (show all 904)
# Title Authors Year
1
Assessment of the frequency criterion for the diagnosis of non-suicidal self-injury disorder in female adolescents with conduct disorder. ( 29957550 )
2018
2
Episodic memory and consciousness in antisocial personality disorder and conduct disorder. ( 29353574 )
2018
3
Conduct disorder in adolescent females: current state of research and study design of the FemNAT-CD consortium. ( 29948230 )
2018
4
Conduct Disorder and Neighborhood Effects. ( 29350996 )
2018
5
Executive Attention and Empathy-Related Responses in Boys with Oppositional Defiant Disorder or Conduct Disorder, With and Without Comorbid Anxiety Disorder. ( 29752662 )
2018
6
MAOA genotype influences neural response during an inhibitory task in adolescents with conduct disorder. ( 29855796 )
2018
7
Does the course of manic symptoms in pediatric bipolar disorder impact the course of conduct disorder? Findings from four prospective datasets. ( 29890451 )
2018
8
A longitudinal analysis of shooter games and their relationship with conduct disorder and cself-reported delinquency. ( 29853012 )
2018
9
Social skills training and play group intervention for children with oppositional-defiant disorders/conduct disorder: Mediating mechanisms in a head-to-head comparison. ( 29347904 )
2018
10
Distinguishing Adolescents With Conduct Disorder From Typically Developing Youngsters Based on Pattern Classification of Brain Structural MRI. ( 29740296 )
2018
11
Sex Differences in the Genetic and Environmental Influences on Self-Reported Non-aggressive and Aggressive Conduct Disorder Symptoms in Early and Middle Adolescence. ( 29948512 )
2018
12
Pregnancy risk factors in relation to oppositional-defiant and conduct disorder symptoms in the Avon Longitudinal Study of Parents and Children. ( 29550610 )
2018
13
Do Callous-Unemotional Traits and Conduct Disorder Symptoms Predict the Onset and Development of Adolescent Substance Use? ( 29455341 )
2018
14
Oppositional defiant disorder/conduct disorder co-occurrence increases the risk of Internet addiction in adolescents with attention-deficit hyperactivity disorder. ( 29865863 )
2018
15
Anatomy of the dorsal default-mode network in conduct disorder: Association with callous-unemotional traits. ( 29413533 )
2018
16
Amygdala-orbitofrontal structural and functional connectivity in females with anxiety disorders, with and without a history of conduct disorder. ( 29348532 )
2018
17
Impact of Drug Adherence on Oppositional Defiant Disorder and Conduct Disorder Among Patients With Attention-Deficit/Hyperactivity Disorder. ( 30192445 )
2018
18
Facial Emotion Recognition and Eye Gaze in Attention-Deficit/Hyperactivity Disorder With and Without Comorbid Conduct Disorder. ( 30071977 )
2018
19
Serum levels of cortisol, dehydroepiandrosterone, and oxytocin in children with attention-deficit/hyperactivity disorder combined presentation with and without comorbid conduct disorder. ( 29324397 )
2018
20
Saliva oxytocin, cortisol, and testosterone levels in adolescent boys with autism spectrum disorder, oppositional defiant disorder/conduct disorder and typically developing individuals. ( 30201120 )
2018
21
Preclinical models of conduct disorder - principles and pharmacologic perspectives. ( 27238913 )
2018
22
The pharmacological treatment of aggression in children and adolescents with conduct disorder. Do callous-unemotional traits modulate the efficacy of medication? ( 28137460 )
2018
23
Preventing Conduct Disorder and Callous Unemotional Traits: Preliminary Results of a School Based Pilot Training Program. ( 28144810 )
2018
24
Can laboratory animals violate behavioural norms? Towards a preclinical model of conduct disorder. ( 28167096 )
2018
25
Reciprocal Relations Between Parenting Behaviors and Conduct Disorder Symptoms in Preschool Children. ( 29468356 )
2018
26
An update on the global prevalence of conduct disorder (2011-2017): Study protocol for a systematic review and meta-analysis. ( 30031216 )
2018
27
Independent predictors of mortality in adolescents ascertained for conduct disorder and substance use problems, their siblings and community controls. ( 30091161 )
2018
28
Distinct brain structure and behavior related to ADHD and conduct disorder traits. ( 30108313 )
2018
29
Focused issue on conduct disorder and aggressive behaviour. ( 30143888 )
2018
30
Multivoxel pattern analysis of structural MRI in children and adolescents with conduct disorder. ( 30145719 )
2018
31
Nosology and subtypes of conduct disorder. ( 30166685 )
2018
32
Understanding the Demographic Predictors and Associated Comorbidities in Children Hospitalized with Conduct Disorder. ( 30181470 )
2018
33
Sex Differences in Spontaneous Brain Activity in Adolescents With Conduct Disorder. ( 30214422 )
2018
34
Commentary on Border et al. (2018): The public health burden of conduct disorder, early mortality and criminal justice involvement. ( 30215875 )
2018
35
Conduct Disorder: Recognition and Management. ( 30365289 )
2018
36
Altered Neuronal Responses During an Affective Stroop Task in Adolescents With Conduct Disorder. ( 30405475 )
2018
37
Associations Between Conduct Disorder, Neurodevelopmental Problems and Psychopathic Personality Traits in a Swedish Twin Youth Population. ( 30459483 )
2018
38
Valence, arousal or both? Shared emotional deficits associated with Attention Deficit and Hyperactivity Disorder and Oppositional/Defiant-Conduct Disorder symptoms in school-aged youth. ( 30529288 )
2018
39
A Retrospective Study of Long Acting Risperidone Use to Support Treatment Adherence in Youth with Conduct Disorder. ( 29073744 )
2017
40
Conduct Disorder ( 29261891 )
2017
41
Sex differences in risk-based decision making in adolescents with conduct disorder. ( 28688012 )
2017
42
Affect recognition among adolescents in therapeutic schools: relationships with posttraumatic stress disorder and conduct disorder symptoms. ( 28503096 )
2017
43
Disrupted small-world brain network topology in pure conduct disorder. ( 29029449 )
2017
44
Boys with Oppositional Defiant Disorder/Conduct Disorder Show Impaired Adaptation During Stress: An Executive Functioning Study. ( 28755013 )
2017
45
Spiritual Psychotherapy for Adolescents with Conduct Disorder: Designing and Piloting a Therapeutic Package. ( 29472952 )
2017
46
Sex Differences in the Relationship Between Conduct Disorder and Cortical Structure inA Adolescents. ( 28735700 )
2017
47
Short- and long-range functional connectivity density alterations in adolescents with pure conduct disorder at resting-state. ( 28377176 )
2017
48
The reliability, concurrent validity and association with salivary oxytocin of the self-report version of the Inventory of Callous-Unemotional Traits in adolescents with conduct disorder. ( 28628793 )
2017
49
Brain structure abnormalities in young women who presented conduct disorder in childhood/adolescence. ( 28695488 )
2017
50
Population cost-effectiveness of the Triple P parenting programme for the treatment of conduct disorder: an economic modelling study. ( 29288334 )
2017

Variations for Conduct Disorder

Expression for Conduct Disorder

Search GEO for disease gene expression data for Conduct Disorder.

Pathways for Conduct Disorder

Pathways related to Conduct Disorder according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.86 ALDH2 CAMK2A COMT GRIN1 MAOA SLC6A3
2
Show member pathways
12.79 CAMK2A COMT DRD2 DRD4 DRD5 GRIN1
3 12.46 CAMK2A COMT DBH GRIN1 TPH1
4 12.21 DRD2 DRD4 DRD5 GRIN1
6
Show member pathways
12.1 ADORA2A CAMK2A DRD5 GRIN1 OXTR
7 12.05 GRIN1 MAOA SLC6A4 TPH1
8
Show member pathways
12.04 ALDH2 MAOA TPH1
9
Show member pathways
12.04 ADORA2A CAMK2A DRD2 DRD5 GRIN1 OXTR
10
Show member pathways
12.02 CAMK2A DRD2 DRD4 DRD5 GRIN1
11
Show member pathways
11.84 DRD2 DRD4 DRD5
12 11.84 MAOA SLC6A4 TPH1
13
Show member pathways
11.83 CAMK2A DRD2 GRIN1 MAOA SLC6A3
14 11.71 DBH MAOA TPH1
15
Show member pathways
11.63 COMT DBH MAOA
16 11.52 CAMK2A GRIN1 RBFOX1
17 11.13 MAOA SLC6A4 TPH1
18
Show member pathways
10.99 ADORA2A DBH MAOA SLC6A3 SLC6A4
19 10.95 DRD2 DRD5
20
Show member pathways
10.83 ALDH2 COMT MAOA
21
Show member pathways
10.8 COMT DBH MAOA TPH1
22 10.74 COMT MAOA
23
Show member pathways
10.7 ALDH2 MAOA
24
Show member pathways
10.44 ALDH2 COMT MAOA SLC6A3 SLC6A4

GO Terms for Conduct Disorder

Cellular components related to Conduct Disorder according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.86 ADORA2A DRD2 DRD4 DRD5 GRIN1 OXTR
2 axon GO:0030424 9.81 ADORA2A COMT DRD2 SLC6A3
3 glutamatergic synapse GO:0098978 9.8 ADORA2A DRD2 DRD4 GRIN1
4 neuron projection GO:0043005 9.77 CAMK2A GRIN1 SLC6A3 SLC6A4 TPH1
5 postsynaptic density GO:0014069 9.73 ADORA2A CAMK2A DRD2 GRIN1
6 postsynaptic membrane GO:0045211 9.71 ADORA2A CAMK2A COMT GRIN1
7 dendrite GO:0030425 9.63 ADORA2A CAMK2A COMT DRD2 DRD4 GRIN1
8 dendritic spine GO:0043197 9.62 CAMK2A COMT DRD2 GRIN1
9 dopaminergic synapse GO:0098691 9.46 DRD2 SLC6A3
10 integral component of presynaptic membrane GO:0099056 9.26 ADORA2A DRD2 SLC6A3 SLC6A4
11 integral component of postsynaptic membrane GO:0099055 8.92 ADORA2A DRD2 SLC6A3 SLC6A4
12 membrane GO:0016020 10.31 ADORA2A CAMK2A COMT DBH DRD2 DRD4
13 plasma membrane GO:0005886 10.22 ADORA2A CAMK2A COMT DRD2 DRD4 DRD5
14 integral component of membrane GO:0016021 10.22 ADORA2A COMT DBH DRD2 DRD4 DRD5

Biological processes related to Conduct Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 9.86 COMT OXTR SLC6A3
2 response to ethanol GO:0045471 9.85 DRD2 GRIN1 SLC6A3
3 response to drug GO:0042493 9.85 ADORA2A COMT DRD2 OXTR SLC6A3 SLC6A4
4 cellular calcium ion homeostasis GO:0006874 9.83 DRD4 DRD5 GRIN1
5 locomotory behavior GO:0007626 9.81 ADORA2A DBH DRD2 SLC6A3
6 memory GO:0007613 9.78 DBH GRIN1 OXTR SLC6A4
7 excitatory postsynaptic potential GO:0060079 9.77 ADORA2A DRD2 GRIN1
8 visual learning GO:0008542 9.73 DBH DRD2 GRIN1
9 social behavior GO:0035176 9.73 DRD4 GRIN1 OXTR SLC6A4
10 negative regulation of blood pressure GO:0045776 9.71 DRD2 DRD5
11 synaptic transmission, glutamatergic GO:0035249 9.71 ADORA2A GRIN1
12 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.71 ADORA2A OXTR
13 arachidonic acid secretion GO:0050482 9.7 DRD2 DRD4
14 eating behavior GO:0042755 9.7 ADORA2A OXTR
15 regulation of long-term neuronal synaptic plasticity GO:0048169 9.7 DRD2 GRIN1
16 behavioral response to cocaine GO:0048148 9.7 DRD2 DRD4
17 regulation of neuronal synaptic plasticity GO:0048168 9.69 CAMK2A GRIN1
18 response to pain GO:0048265 9.69 COMT DBH
19 dopamine receptor signaling pathway GO:0007212 9.68 DRD2 DRD4
20 negative regulation of protein secretion GO:0050709 9.68 DRD2 DRD4
21 positive regulation of long-term synaptic potentiation GO:1900273 9.68 ADORA2A DRD2
22 response to iron ion GO:0010039 9.68 DRD2 SLC6A3
23 startle response GO:0001964 9.67 DRD2 GRIN1
24 neurotransmitter biosynthetic process GO:0042136 9.67 SLC6A3 SLC6A4
25 synaptic transmission, dopaminergic GO:0001963 9.67 ADORA2A DRD2 DRD5
26 positive regulation of renal sodium excretion GO:0035815 9.66 ADORA2A DRD2
27 positive regulation of urine volume GO:0035810 9.66 ADORA2A DRD2
28 maternal behavior GO:0042711 9.65 DBH OXTR
29 suckling behavior GO:0001967 9.65 GRIN1 OXTR
30 positive regulation of synaptic transmission, GABAergic GO:0032230 9.64 ADORA2A OXTR
31 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.64 DRD2 DRD4
32 catecholamine metabolic process GO:0006584 9.63 COMT MAOA
33 inhibitory postsynaptic potential GO:0060080 9.63 ADORA2A DRD4
34 dopamine metabolic process GO:0042417 9.63 COMT DRD2 DRD4
35 neurotransmitter catabolic process GO:0042135 9.62 COMT MAOA
36 regulation of dopamine metabolic process GO:0042053 9.62 DRD4 SLC6A3
37 response to cocaine GO:0042220 9.62 DRD2 DRD5 OXTR SLC6A3
38 adenohypophysis development GO:0021984 9.61 DRD2 SLC6A3
39 monoamine transport GO:0015844 9.61 SLC6A3 SLC6A4
40 negative regulation of voltage-gated calcium channel activity GO:1901386 9.6 DRD2 DRD4
41 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.58 DRD2 DRD5
42 regulation of systemic arterial blood pressure by vasopressin GO:0001992 9.58 DRD5 OXTR
43 behavioral response to ethanol GO:0048149 9.58 DBH DRD2 DRD4
44 sperm ejaculation GO:0042713 9.57 OXTR SLC6A4
45 associative learning GO:0008306 9.56 DBH DRD2 DRD5 GRIN1
46 fear response GO:0042596 9.55 DBH DRD4
47 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.54 DRD2 DRD4
48 response to histamine GO:0034776 9.52 DRD2 DRD4
49 prepulse inhibition GO:0060134 9.46 ADORA2A DRD2 GRIN1 SLC6A3
50 dopamine catabolic process GO:0042420 9.26 COMT DBH MAOA SLC6A3

Molecular functions related to Conduct Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.8 ADORA2A DRD2 DRD4 DRD5 OXTR
2 drug binding GO:0008144 9.43 DRD2 DRD4 SLC6A3
3 neurotransmitter:sodium symporter activity GO:0005328 9.37 SLC6A3 SLC6A4
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.32 DRD2 DRD4
5 monoamine transmembrane transporter activity GO:0008504 9.16 SLC6A3 SLC6A4
6 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD2 DRD4 DRD5
7 dopamine binding GO:0035240 8.92 DRD2 DRD4 DRD5 SLC6A3

Sources for Conduct Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....